Drug Sales Trends for VIVITROL

Select year for charts:

[2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 ]

Annual Sales Revenues and Units Sold for VIVITROL

These sales figures are drawn from a US national survey of drug expenditures

Drug Name	Revenues (USD)	Units	Year
VIVITROL			2022
VIVITROL			2021
VIVITROL			2020
VIVITROL			2019
VIVITROL			2018
VIVITROL			2017
VIVITROL			2016

Market Analysis and Sales Projections for VIVITROL (Naltrexone for Extended-Release Injectable Suspension)

Last updated: July 27, 2025

Introduction

VIVITROL (naltrexone for extended-release injectable suspension) is a prescription medication developed by Alkermes, primarily used to treat opioid dependence and alcohol use disorder (AUD). Its unique extended-release formulation allows for monthly injectable administration, facilitating improved adherence and outcomes for patients with substance use disorders (SUD). As a critical player in the addiction treatment market, VIVITROL’s market dynamics and sales performance are influenced by regulatory, therapeutic, and competitive factors. This analysis explores the current market landscape and projects its future sales trajectory, providing essential insights for stakeholders.

Market Landscape

Global and Regional Market Size

The global substance use disorder (SUD) treatment market was valued at approximately USD 12 billion in 2021 and is expected to grow at a Compound Annual Growth Rate (CAGR) of 7-9% through 2028 (Grand View Research). Key drivers include increasing opioid epidemic severity, expanding awareness of addiction treatments, and the development of long-acting formulations like VIVITROL.

Regionally, North America dominates the market, accounting for over 60% of sales. This is attributable to heightened opioid crisis awareness, government funding, and reimbursement frameworks favoring innovative treatments. Europe represents the second-largest market, with increasing adoption of injectable therapies for SUD.

Therapeutic Market Segments

VIVITROL competes chiefly in two segments:

1. Opioid Dependence Treatment: Approved for relapse prevention post-detoxification.
2. Alcohol Use Disorder: Approved for preventing relapse in alcohol dependence.

Combined, these segments represent an estimated USD 4–5 billion annual market, with substantial growth expected as the opioid epidemic exacerbates and behavioral health initiatives expand.

Competitive Positioning

VIVITROL faces competition primarily from oral naltrexone, methadone, buprenorphine, and emerging long-acting formulations. Notably, XR-NTX's monthly dosing offers superior adherence compared to oral options, giving it a strategic advantage. Other competitors include Sab Recovery’s injectable medications, though VIVITROL maintains a significant market share due to its established safety profile and widespread prescriber familiarity.

Sales Performance and Trends

Historical Sales Overview

VIVITROL's global sales have experienced consistent growth since approval in 2010 for alcohol dependence and subsequently for opioid dependence in 2012. According to Alkermes' financial reports, VIVITROL generated approximately USD 726 million in net revenue in 2022, a growth of about 14% from USD 637 million in 2021 [1].

The North American market accounted for around 85% of revenues, underpinned by high insured patient populations and robust reimbursement pathways. Sales growth is driven by increasing prescriptions, broader indication approvals, and a focus on improving patient adherence.

Market Penetration and Adoption

Despite establishing a strong presence, VIVITROL’s penetration remains limited by factors such as clinician familiarity, patient acceptance of injectable therapy, and reimbursement barriers. The COVID-19 pandemic initially disrupted distribution channels but was compensated by accelerated telehealth adoption and prioritization of addiction treatment.

Pricing Dynamics

The average wholesale price (AWP) for VIVITROL is approximately USD 1,200–1,500 per dose. Payer negotiations and formulary placements significantly influence actual reimbursement and net sales.

Future Sales Projections

Factors Influencing Sales Growth

1. Increasing Opioid and Alcohol Dependence Prevalence: The continuing opioid crisis underscores the need for long-acting antagonists. The CDC estimates over 100,000 overdose deaths in the U.S. in 2021 alone [2].

2. Regulatory Advances and Approvals: Recent approvals for additional indications, such as injection for opioid dependence in adolescents, could expand market size.

3. Payer and Policy Support: Growing inclusion of VIVITROL in public and private insurance formularies enhances accessibility.

4. Innovations and Pipeline Developments: Alkermes’ pipeline, including new formulations and combination therapies, could further boost sales.

Projected Sales Figures

Based on industry reports and market trends, VIVITROL’s global sales are expected to grow at a CAGR of approximately 9-11% through 2028, reaching between USD 1.3 billion and USD 1.6 billion annually by 2028 [3].

This projection considers increased uptake in emerging markets, expanded regulatory approvals, and ongoing efforts to reduce barriers to treatment. North America will remain the dominant region, but substantial growth is anticipated in Europe and Asia-Pacific owing to increased recognition of SUD as a critical healthcare issue.

Challenges and Risks

• Reimbursement and Cost Barriers: High treatment costs may limit access in low-income populations.
• Competition from Generics and New Formulations: The emergence of biosimilars or new long-acting agents could erode market share.
• Stigma and Patient Acceptance: Social stigma and injection aversion may hinder adoption.
• Regulatory and Policy Changes: Shifts in healthcare policy and priorities can impact market growth.

---

Key Takeaways

• Market Dominance and Growth: VIVITROL maintains a significant share of the long-acting SUD treatment market, with projected sales steadily increasing driven by opioid and AUD epidemics.
• Strategic Positioning: Its once-monthly administration confers adherence advantages, critical in managing chronic conditions like addiction.
• Expansion Opportunities: Increasing prescribing in emerging markets, expanded indications, and pipeline innovations present growth avenues.
• Pricing and Access: Continued payer negotiations and healthcare policy developments will influence future sales potential.
• Competitive Landscape: Ongoing innovation and market entrants pose a threat but currently, VIVITROL's established profile sustains its market position.

---

FAQs

1. What are the main drivers behind VIVITROL’s sales growth?
The escalating opioid epidemic, expanding indications (including AUD), improved reimbursement, and increased prescriber awareness drive VIVITROL’s sales expansion.

2. How does VIVITROL compare with oral naltrexone?
VIVITROL’s extended-release formulation ensures monthly adherence, reducing non-compliance issues associated with daily oral naltrexone, thus improving relapse prevention outcomes.

3. What are the key challenges facing VIVITROL’s market penetration?
Barriers include high treatment costs, stigma associated with injectable therapies, limited access in low-income regions, and competition from other treatment modalities.

4. What is the future outlook for VIVITROL’s sales in emerging markets?
As SUD awareness increases globally and healthcare infrastructure improves, sales in emerging markets are expected to grow significantly, supported by regulatory approvals and global health initiatives.

5. How might new competitors impact VIVITROL’s market share?
Innovative long-acting formulations and biosimilars could challenge VIVITROL’s dominance, emphasizing the need for continued R&D and strategic positioning by Alkermes.

---

References

1. Alkermes 2022 Financial Reports.
2. CDC. Alcohol and Opioid Overdose Data. 2022.
3. MarketResearch.com. SUD Treatment Market Forecast, 2023-2028.